Pharmac Notification: Decision to fund treatments for multiple sclerosis, eye conditions, breast cancer and lung cancer

Kia ora,Pharmac is funding five medicines through a multiproduct agreement with Roche. These medicines will provide new or improved treatment options for people with multiple sclerosis, eye conditions, breast cancer and lung cancer.The medicines we are funding are:

• Ocrelizumab (Ocrevus SC): a new injection option for multiple sclerosis

• Pertuzumab with trastuzumab (Phesgo): a new combined injection for HER2-positive metastatic breast cancer

• Faricimab (Vabysmo): for diabetic macular oedema and wet age-related macular degeneration (eye conditions)

• Entrectinib (Rozlytrek): for ROS1-positive non-small cell lung cancer

• Bevacizumab (Avastin): securing ongoing access for people with eye conditions

These medicines will be funded from 1 December 2025.

➤ Decision to fund treatments for multiple sclerosis, eye conditions, breast cancer and lung cancer

Ngā mihi,

Emma Clarke | Senior Therapeutic Group Manager

Pharmac | Te Pātaka Whaioranga | P: 0800 660 050 | www.pharmac.govt.nz